EAM Global Investors’s Revance Therapeutics, Inc. RVNC Stock Holding History

EAM Global Investors’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-63,279	Closed	-$1.71M	–	245
2022 Q3	$1.71M	Buy	+63,279	New	+$1.28M	0.45%	103
2020 Q3	–	Sell	-40,541	Closed	-$990K	–	179
2020 Q2	$990K	Sell	40,541 -69,398	-63%	-$1.37M	0.45%	108
2020 Q1	$1.63M	Sell	109,939 -26,504	-19%	-$548K	0.95%	42
2019 Q4	$2.21M	Buy	+136,443	New	+$2.12M	0.89%	37
2018 Q2	–	Sell	-44,898	Closed	-$1.38M	–	189
2018 Q1	$1.38M	Hold	44,898	–	–	0.72%	36
2017 Q4	$1.6M	Buy	+44,898	New	+$1.29M	0.82%	10

Other funds holding RVNC

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM Global Investors's RVNC Position: Q4 2022 in Review

EAM Global Investors sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2022, closing a stake of 63,279 shares — an estimated $1.71M sold.

EAM Global Investors first reported a position in RVNC in Q4 2017 and held it in 6 quarters. The position peaked at $2.21M in Q4 2019. 193 funds tracked by Wall St. Rank hold RVNC as of Q4 2022.

EAM Global Investors reported no remaining Revance Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
EAM Global Investors sold 63,279 Revance Therapeutics, Inc. shares in Q4 2022, an estimated $1.71M.
EAM Global Investors first reported a position in Revance Therapeutics, Inc. in Q4 2017 and held it in 6 quarters.
EAM Global Investors's Revance Therapeutics, Inc. position peaked at $2.21M in Q4 2019.
193 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2022.

Based on EAM Global Investors's 13F filing for Q4 2022, filed 14 Feb 2023.